Priyanka joined Novo Ventures (US) Inc. in 2022 as a partner in the Boston office.
Priyanka brings over 15 years of Pharmaceutical and Biotech industry experience across Venture Capital, R&D and Business Development. Previously, she was a Venture Partner at Longwood Fund and served on the board of Interius Bio. Prior to Longwood, she was the Managing Director & Head of Ipsen Ventures, responsible for portfolio management, limited partnerships, and the Ipsen Innovation Center. Before joining Ipsen, she served as Investment Director at two corporate venture funds, AbbVie Ventures and Baxter Ventures. She has served on the board of Syntimmune (acquired by Alexion), Sanifit (acquired by Vifor Pharma), Artios, Pyxis Oncology (PYXS), and Xilio Therapeutics (XLO), among others. Prior to venture capital, Priyanka was a research scientist with Baxter R&D in drug metabolism and pharmacology and at the School of Pharmacy at the University of Washington.
Priyanka earned her Ph.D. in Biochemistry and M.S. in Bioinformatics from the Georgia Institute of Technology, M.S. in Pharmaceutics from the University of Washington and M.S. in Biology from the Indiana University of Pennsylvania. She holds a B.S. in Biology and Chemistry from the University of Delhi.